Retatrutide: The Complete Guide to the Triple-Agonist Peptide

Retatrutide is the single most-discussed name in metabolic research today. As a
“triple agonist,” it goes a step beyond the single- and dual-pathway compounds that came
before it — and the early numbers are why everyone is paying attention.

What “triple agonist” means

Most metabolic peptides activate one or two hormone pathways. Retatrutide activates three
at once:

• GLP-1 — reduces appetite and slows gastric emptying.
• GIP — supports insulin sensitivity and energy balance.
• Glucagon — the novel third arm, associated with increased energy expenditure
  and fat oxidation.

The glucagon pathway is what sets retatrutide apart. Where other compounds mainly reduce intake, the
glucagon arm is studied for increasing output — how much energy the body burns.

The clinical signal

Early-phase trial data place retatrutide at the top of the group, with average body-weight reductions
reported up to roughly 22–24% in study settings — surpassing single- and
dual-agonist compounds. Research into optimal dosing and long-term use is ongoing.

Figures reflect published clinical-trial averages and are
presented for research context only.

Handling and protocol notes

• Titrate slowly — gradual dose escalation is the norm in the literature.
• Reconstitute gently and refrigerate; swirl, never shake.
• Measure precisely with the Dosage Calculator.
• Track objectively — weight, measurements, and how you feel.

Where Quantum fits

Quantum supplies Retatrutide as a Canadian-sourced, third-party-tested research
compound. Compare it with the dual-agonist option in our
Retatrutide vs Tirzepatide comparison.